Linked Life Data

19888533

Source:http://linkedlifedata.com/resource/pubmed/id/19888533

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-11-5
pubmed:abstractText
Men have a higher incidence of cardiovascular disease (CVD) than women of similar age, and it has been suggested that testosterone may influence the development of CVD. Recently, we demonstrated that elderly men with low testosterone levels had lower plasma levels of free tissue factor pathway inhibitor (TFPI) Ag associated with shortened tissue factor (TF)-induced coagulation initiation in a population based case-control study. Our hypothesis was that one year of testosterone treatment to physiological levels in elderly men would increase the levels of free TFPI Ag in plasma and have a favorable effect on TF-induced coagulation. Twenty-six men with low testosterone levels (< or =11.0 nM) were randomly assigned to treatment with intramuscular testosterone depot injections (testosterone undecanoate 1,000 mg) or placebo in a double-blinded study. Each participant received a total of five injections, at baseline, 6, 16, 28 and 40 weeks, and TF-induced thrombin generation ex vivo and plasma free TFPI Ag were measured after one year. At the end of the study total and free testosterone levels were significantly higher in the testosterone treated group (14.9 +/- 4.5 nM vs. 8.1 +/- 2.4 nM; p < 0.001, and 363.3 +/- 106.6 pM vs. 187.3 +/- 63.2 pM; p < 0.001, respectively). Testosterone treatment for one year did neither cause significant changes in TF-induced thrombin generation ex vivo nor changes in plasma levels of free TFPI Ag. In conclusion, normalising testosterone levels by testosterone treatment for 12 months in elderly men did not affect TF-induced coagulation or plasma TFPI levels. The potential antithrombotic role of testosterone therapy remains to be elucidated.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0340-6245
pubmed:author
pubmed:issnType
Print
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
945-50
pubmed:dateRevised
2010-3-30
pubmed:meshHeading
pubmed-meshheading:19888533-Aged, pubmed-meshheading:19888533-Antigens, pubmed-meshheading:19888533-Cardiovascular Diseases, pubmed-meshheading:19888533-Case-Control Studies, pubmed-meshheading:19888533-Delayed-Action Preparations, pubmed-meshheading:19888533-Double-Blind Method, pubmed-meshheading:19888533-Factor VII, pubmed-meshheading:19888533-Follow-Up Studies, pubmed-meshheading:19888533-Humans, pubmed-meshheading:19888533-Hypogonadism, pubmed-meshheading:19888533-Injections, Intramuscular, pubmed-meshheading:19888533-Lipids, pubmed-meshheading:19888533-Lipoproteins, pubmed-meshheading:19888533-Male, pubmed-meshheading:19888533-Middle Aged, pubmed-meshheading:19888533-Risk Factors, pubmed-meshheading:19888533-Testosterone, pubmed-meshheading:19888533-Thrombin, pubmed-meshheading:19888533-Thrombophilia, pubmed-meshheading:19888533-Thromboplastin, pubmed-meshheading:19888533-Time Factors
pubmed:year
2009
pubmed:articleTitle
Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
pubmed:affiliation
Department of Medicine, Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't